Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Order Online! Now! Get your $50 coupon for online order. 
Order Online! Now! Get your $50 coupon for online order.
Our limited edition HOLIDAYS LLAMA is here! Place any order now to recieve one! Earn Loyalty Rewards! Up to $155 Amazon Gift Card
Time Limited Offer: Welcome Gift for New Customers ! Time Limited Offer: Welcome Gift for New Customers !
1. Huge drug market for IPF
(1) High mortality: The total IPF patient population worldwide was 1.27 M in 2019. The five-year survival rate from the initial diagnosis of an Acute IPF is 18.4%, which is less than that of most cancers.
(2) Huge drug market: only two marketed drugs for IPF, Pirfenidone (PFD) and Nintedanib. PFD sold 1.19 billion in 2019 even though there is severe AE and limited efficacy.
(3) IPF patients need long-term and lifelong medication. However, both marketed drugs are just recommended as appropriate in China. The class I recommended drugs is still in an empty position.
2. Asset showed more potent fibrosis inhibition activities in vitro, and greater improvement in vivo than PFD.
3. Excellent anti-tumor effect in vivo.
(1) Asset showed much stronger INFα and TGF-β1 inhibitory activity and much less cell proliferation than PFD.
(2) Asset showed concentration-dependently inhibition of α-SMA and COL1A1 protein in LX-2 cells.
(3) Asset showed great improvement in the efficacy evaluation of fibrosis score and artery lesions, resulting in better efficacy with a 10-fold lower dose than that of PFD.
3. Improved PK, broad safety window, and lower risk in safety issues.
(1) Asset QD vs PFD TID T1/2 (po.) in Rat: Asset = 8.12 h vs PFD = 0.40 h
(2) Compared with the two marketed drugs, the asset showed a broader safety window with a lower risk of safety issues in the preclinical study.
4. Excellent phase 1 data.
(1) Absorbed quickly (Tmax= 2~3 h).
(2) Well-absorbed and the therapeutic dose is estimated at 200 mg, meeting once daily dosing QD.
(3) Good safety, few AEs, and all are mild, no SAEs and death cases reported.
1. Asset type: TNFα and TGF-β1 inhibition
2. Indication: Idiopathic Pulmonary Fibrosis (IPF)
3. Research phase: Phase 2
4. Characteristic: FDA ODD for IPF
5. Cooperation demands: License-out or co-development
6. Research progress：
(1) Phase 2 trial is ongoing in both China and US.
(2) Good safety and few AEs.
(3) Suit for QD, remains better clinical compliance.
ACROBiosystems offers a wide selection of Matrigengel basement membrane extracts. Different versions – including phenol red-free, high concentration, iPSC culturing, organoid culturing – are all available for your specific needs to support 3D cell culture!
ComboX is a new brand of ACROBiosystems. ComboX products include our Streptavidin series products, coated plates, isotype controls for antibody and fusion protein drug research, and general-purpose antibodies.
To enable antibody characterization methodsACROBiosystems has developed a series of enzymes.such as ldeS, SpeB, EndoH, and Endo S proteases, toassist with the characterization of antibodies and theirrelated post-translational modifications (PTMs)
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro is ACROBiosystems brand focused on neuroscience research, providing high-quality important proteins including therapeutic and diagnostic research proteins, PFFs and recombinant neuro factors, etc. to advance neuroscience research.
This web search service is supported by Google Inc.
A-Z
